Clinical trials: Schizophrenia
Schizophrenia, Cognition Disorders
The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects.
This study in young and elderly healthy subjects will investigate the effect of nicotine on arousal, cognitive task and social cognition after acute dose administration.
- Trial name
- NCT01181934
- Testing
- A643 (nicotine)
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Bipolar I Disorder, Schizophrenia
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
This is a single-center open-label study to be conducted in the United States in subjects with bipolar I disorder or schizophrenia.
- Trial name
- NCT04127058
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)
This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia.
- Trial name
- NCT01235585
- Testing
- bitopertin [RO4917838]
- Where
- 120 sites in United States, Brazil and 12 more
- Volunteers
- 597 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
This will be a randomized, double-blind, placebo-controlled study consisting of a screening period, a conversion phase (Phase 1), a stabilization phase (Phase 2), and a double-blind maintenance treatment phase (Phase 3), and a…
- Trial name
- ATTAIN 266 (NCT01149655)
- Testing
- Aripiprazole
- Where
- 52 sites in United States, India and 5 more
- Volunteers
- 252 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.
- Trial name
- NCT01626885
- Testing
- MP-214
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia
Phase I Trial of HHK101 in Patients With Schizophrenia
This study aims to learn how the study drug is absorbed by the body, check for possible side effects, and see if the drug may help improve symptoms in patients with schizophrenia.
- Trial name
- NCT07815210
- Testing
- HHK101-Single Dose 1, HHK101-Single Dose 2, HHK101-Single Dose 3
- Where
- 4 sites in China
- Volunteers
- 88 people
- Sponsor
- Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
Schizophrenia
A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate
The purpose of this study is to evaluate the concentration of paliperidone in the blood after intramuscular injection in upper arm (deltoid muscle) or in the buttock (gluteal muscle) in patients with schizophrenia.
- Trial name
- NCT01110317
- Testing
- paliperidone palmitate 100 mg
- Volunteers
- 49 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia
The purpose of this study is to assess the efficacy and safety of 1.5 mg/day dose of paliperidone Extended Release (ER) as compared with placebo when used to treat patients with schizophrenia.
- Trial name
- NCT00524043
- Testing
- Paliperidone ER
- Where
- 20 sites in United States, India and 1 more
- Volunteers
- 201 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Bipolar I Disorder
A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder
The purpose of this trial is to determine the safety and tolerability of multiple-dose administrations of aripiprazole, to establish the similarity of aripiprazole concentrations on the last day of the dosing interval following…
- Trial name
- NCT04030143
- Testing
- Aripiprazole
- Where
- 19 sites in United States
- Volunteers
- 266 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
This study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of schizophrenia in adolescents.
- Trial name
- NCT00051298
- Testing
- Olanzapine
- Where
- 25 sites in United States, Russia
- Volunteers
- 107 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Relapse Prevention Study in Patients With Schizophrenia
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
- Trial name
- REPRIEVE (NCT01291511)
- Testing
- Iloperidone
- Where
- 63 sites in United States, India and 1 more
- Volunteers
- 635 people
- Sponsor
- Vanda Pharmaceuticals
Tardive Dyskinesia
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
The primary objective is to assess the safety and effectiveness of Pyridoxal 5'-Phosphate on the reduction of expressed symptoms of tardive dyskinesia in patients with schizophrenia and schizoaffective disorders.
- Trial name
- NCT00917293
- Testing
- Pyridoxal 5'-Phosphate
- Where
- 4 sites in Canada, India
- Volunteers
- 53 people
- Sponsor
- Medicure
Schizophrenia
The Effect of Ketamine on Attentiveness
The objective of this study is to develop an exploratory design for future Proof-of-Concept trials which reliably and accurately measure the central nervous system (CNS) effects of potentially new drugs that oppose the effects of…
- Trial name
- NCT01165294
- Testing
- ketamine
- Volunteers
- 24 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
This study will evaluate the efficacy of ALKS 3831 in adult subjects with acute exacerbation of schizophrenia.
- Trial name
- NCT02634346
- Testing
- ALK3831, Olanzapine
- Where
- 31 sites in United States, Bulgaria and 2 more
- Volunteers
- 403 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
Bioequivalence Fasting Study in Patients
To compare and evaluate the oral bioavailability of Asenapine Sublingual Tablets, 10 mg manufactured by AMNEAL PHARMACEUTICALS, USA with SAPHRIS® (asenapine) sublingual tablets, 10 mg.
- Trial name
- NCT02072954
- Testing
- Asenapine Sublingual Tablets 10 mg
- Where
- 2 sites in India
- Volunteers
- 48 people
- Sponsor
- Amneal Pharmaceuticals, LLC
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06388551
- Testing
- LY03017
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits
The primary objective of this study is to evaluate if adjunctive armodafinil treatment can improve the cognitive deficits in patients with schizophrenia
- Trial name
- NCT00487942
- Testing
- armodafinil
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cephalon
Schizophrenia
Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
This is an open label study in 4 cohort of 4 healthy volunteers each designed to evaluate the dopamine receptor occupancy of LB-102 at various doses and timepoints.
- Trial name
- NCT04588129
- Testing
- LB-102
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- LB Pharmaceuticals Inc.
Negative Symptoms of Schizophrenia
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate…
- Trial name
- NCT07565428
- Testing
- Roluperidone, risperidone, aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 380 people
- Sponsor
- Minerva Neurosciences
Schizophrenia
A Switch Study of BMS-337039 in Schizophrenic Out-patients
The purpose of this clinical research study is to evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general…
- Trial name
- NCT00232687
- Testing
- Aripiprazole
- Where
- 72 sites in Austria, Belgium and 8 more
- Volunteers
- 450 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.